Granules India Limited will host an analyst and investor meeting in London on June 23 and 24, 2026, as part of the IIFL Invest India Conference. The company stated that no unpublished price-sensitive information would be shared during these interactions.

Officials from the company will engage with analysts, investors, and funds through both one-to-one and group meetings. The schedule remains tentative and subject to change due to potential difficulties from the company or the attendees.

The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chaitanya Tummala, Company Secretary and Compliance Officer, signed the intimation on June 15, 2026.

The company has made its latest Investor Presentation available on its official website for stakeholders seeking additional context.

Granules Pharmaceuticals, a subsidiary of Granules India Limited , has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Chantilly facility. The inspection concluded with a Voluntary Action Indicated (VAI) classification, recording four observations at the site. The company communicated this development to the National Stock Exchange of India Limited and BSE Limited on June 03, 2026.

USFDA Inspection Outcome

The USFDA issued the EIR following a completed inspection of the Chantilly facility. The inspection recorded four observations, and the facility has been classified under the Voluntary Action Indicated (VAI) category. A VAI classification signifies that while observations were noted during the inspection, the USFDA does not consider the findings to warrant mandatory regulatory action against the facility.

Key details of the regulatory development are summarised below:

Significance of the VAI Classification

The VAI classification is one of three possible outcomes following a USFDA facility inspection, the others being No Action Indicated (NAI) and Official Action Indicated (OAI). A VAI status indicates that inspectional observations were made, but these do not rise to the level requiring official regulatory action. This outcome reflects the facility's overall compliance standing with USFDA standards following the inspection with four observations.